Default Category
-
SeaMicro
Mark Leslie, Sara RosenthalCase SGSB-E409-EEntrepreneurshipLaunched in 2007, SeaMicro developed one of the most innovative server products to hit the market in over a decade. The SM10000 consumed one-quarter the power and space of conventional server products, thereby addressing a significant and growing pain point, particularly among Web 2.0 companies. As these companies increased their computer power through the addition of tens of thousands of servers, their data centers expanded as well, creating m...Starting at €8.20
-
Imprimis (B)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717496-EEntrepreneurshipThis case is a supplement to Imprimis (Case A). It describes the company's decision to enter into the pharmaceutical compounding business in 2013-14. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients' eyes post-cataract surgery, with the aim of replacing a complex regimen of prescription eye drops. After a successful launch of the compounded medication, Imprimis ran into complica...Starting at €5.74
-
SeaMicro - Teaching Note
Mark Leslie, Sara RosenthalTeaching Note SGSB-E409TN-EEntrepreneurshipLaunched in 2007, SeaMicro developed one of the most innovative server products to hit the market in over a decade. The SM10000 consumed one-quarter the power and space of conventional server products, thereby addressing a significant and growing pain point, particularly among Web 2.0 companies. As these companies increased their computer power through the addition of tens of thousands of servers, their data centers expanded as well, creating m...Starting at €0.00
-
SeaMicro - Moment of Decision
Mark Leslie, Sara RosenthalCase SGSB-E459-EEntrepreneurshipThis case, GSB No. E-459, explores the SeaMicro CEO’s decision of whether or not to sell the company in early 2012. SeaMicro, a developer of low-power servers, has risen quickly as an innovative and significant force in a server market dominated by giants, including HP and Dell. In the fall of 2011, the company is approached by AMD, the industry’s second largest microprocessor manufacturer behind Intel. AMD has faced challenging times in the rec...Starting at €8.20
-
Imprimis (D)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717498-EEntrepreneurshipThis case is a supplement to Imprimis (Case A), Imprimis (Case B), and Imprimis (Case C). It describes Imprimis's 2015 decision to develop a $1 per pill compounded alternative to Daraprim, the branded drug that had recently undergone an extreme price hike, raising its price to $750/pill. Imprimis also created compounded alternatives to several other branded drugs, and made investments to increase its manufacturing capabilities. The company now ha...Starting at €5.74
-
SeaMicro - Moment of Decision - Teaching Note
Mark Leslie, Sara RosenthalTeaching Note SGSB-E459TN-EEntrepreneurshipThis case, GSB No. E-459, explores the SeaMicro CEO’s decision of whether or not to sell the company in early 2012. SeaMicro, a developer of low-power servers, has risen quickly as an innovative and significant force in a server market dominated by giants, including HP and Dell. In the fall of 2011, the company is approached by AMD, the industry’s second largest microprocessor manufacturer behind Intel. AMD has faced challenging times in the rec...Starting at €0.00
-
Imprimis (A)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717426-EEntrepreneurshipThis case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The A case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in 2013. At the time, Imprimis was in the process of seeking FDA approval for a branded drug called Impracor. This process, already difficult, was further complicated by recent manufactur...Starting at €8.20
-
Imprimis (C)
Casadesus-Masanell, Ramon; Elterman, Karen; Appel, MarcCase HBS-717497-EEntrepreneurshipThis case is a supplement to Imprimis (Case A) and Imprimis (Case B). Set in 2015, it first describes Imprimis's decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the problem of high drug prices in the United States. Recent, drastic price hikes on pharmaceutical drugs, such as those initiated by Turing Pharmaceuticals under CEO ...Starting at €5.74